| Toll-like receptor signaling pathway |
1.81 |
1.51e-1 |
94/104 (90.38%) |
SPP1;LY96;CXCL9;...
|
| Phagosome |
1.75 |
1.31e-1 |
118/152 (77.63%) |
HLA-DRA;HLA-DRB1;THBS2;...
|
| Propanoate metabolism |
1.70 |
1.31e-1 |
30/34 (88.24%) |
PCCB;DLD;ABAT;...
|
| Collecting duct acid secretion |
1.68 |
1.34e-1 |
22/27 (81.48%) |
ATP6V0E2;ATP6V1D;CA2;...
|
| Caffeine metabolism |
1.64 |
1.53e-1 |
5/6 (83.33%) |
NAT1;XDH;CYP2A6;...
|
| Vibrio cholerae infection |
1.64 |
1.29e-1 |
44/50 (88%) |
ATP6V0E2;ATP6V1D;KDELR3;...
|
| Asthma |
1.62 |
1.48e-1 |
25/31 (80.65%) |
HLA-DRA;HLA-DRB1;CD40;...
|
| Antigen processing and presentation |
1.62 |
1.34e-1 |
60/78 (76.92%) |
HLA-DRA;CD74;HLA-DRB1;...
|
| One carbon pool by folate |
1.61 |
1.30e-1 |
15/20 (75%) |
SHMT1;SHMT2;MTHFD2;...
|
| Allograft rejection |
1.60 |
1.31e-1 |
32/38 (84.21%) |
HLA-DRA;HLA-DRB1;CD40;...
|
| Systemic lupus erythematosus |
1.59 |
1.39e-1 |
45/135 (33.33%) |
HLA-DRA;HLA-DRB1;C1QA;...
|
| Valine, leucine and isoleucine degradation |
1.58 |
1.36e-1 |
42/48 (87.5%) |
PCCB;DLD;ALDH9A1;...
|
| Glycine, serine and threonine metabolism |
1.57 |
1.39e-1 |
31/40 (77.5%) |
GATM;SHMT1;DLD;...
|
| Type I diabetes mellitus |
1.56 |
1.38e-1 |
38/43 (88.37%) |
HLA-DRA;HLA-DRB1;HLA-F;...
|
| Glyoxylate and dicarboxylate metabolism |
1.55 |
1.41e-1 |
23/30 (76.67%) |
SHMT1;PCCB;DLD;...
|
| Drug metabolism |
1.52 |
1.81e-1 |
78/151 (51.66%) |
FMO2;GSTT1;CYP3A5;...
|
| Viral myocarditis |
1.50 |
1.98e-1 |
53/60 (88.33%) |
HLA-DRA;HLA-DRB1;CD40;...
|
| Staphylococcus aureus infection |
1.49 |
2.01e-1 |
72/95 (75.79%) |
HLA-DRA;HLA-DRB1;DEFB1;...
|
| Bile secretion |
1.48 |
1.92e-1 |
68/90 (75.56%) |
UGT2B28;AQP9;UGT2B17;...
|
| Protein export |
1.48 |
1.86e-1 |
17/23 (73.91%) |
SRP54;SEC63;OXA1L;...
|
| Protein processing in endoplasmic reticulum |
1.47 |
1.91e-1 |
127/171 (74.27%) |
CRYAB;CALR;CKAP4;...
|
| Malaria |
1.47 |
1.86e-1 |
44/50 (88%) |
CCL2;THBS2;TLR4;...
|
| Neomycin, kanamycin and gentamicin biosynthesis |
1.45 |
2.03e-1 |
5/5 (100%) |
HK3;HKDC1;HK2
|
| Coronavirus disease |
1.45 |
1.98e-1 |
215/232 (92.67%) |
RPS4Y1;CCL2;IKBKE;...
|
| Metabolism of xenobiotics by cytochrome P450 |
1.45 |
1.92e-1 |
49/77 (63.64%) |
GSTT1;CYP3A5;UGT2B28;...
|
| Graft-versus-host disease |
1.44 |
1.93e-1 |
32/42 (76.19%) |
HLA-DRA;HLA-DRB1;HLA-F;...
|
| Pentose and glucuronate interconversions |
1.44 |
1.87e-1 |
17/34 (50%) |
AKR1B10;UGT2B28;UGT2B17;...
|
| Tuberculosis |
1.44 |
1.86e-1 |
159/180 (88.33%) |
HLA-DRA;CD74;HLA-DRB1;...
|
| Ascorbate and aldarate metabolism |
1.43 |
1.86e-1 |
15/30 (50%) |
UGT2B28;UGT2B17;ALDH9A1;...
|
| Cysteine and methionine metabolism |
1.41 |
2.02e-1 |
43/50 (86%) |
ADI1;AHCYL2;ENOPH1;...
|
| ECM-receptor interaction |
-1.32 |
3.67e-1 |
80/88 (90.91%) |
SV2B;ITGA7;ITGA4;...
|
| Amoebiasis |
-1.34 |
3.44e-1 |
99/102 (97.06%) |
IL6;RAB5C;CD1D;...
|
| Viral protein interaction with cytokine and cytokine re... |
-1.35 |
3.24e-1 |
84/100 (84%) |
IL6;IL18R1;CXCR5;...
|
| Focal adhesion |
-1.35 |
3.31e-1 |
180/201 (89.55%) |
ITGA7;ILK;RAC3;...
|
| Alzheimer disease |
-1.36 |
3.35e-1 |
279/369 (75.61%) |
CALML5;SDHD;NDUFA6;...
|
| Cushing syndrome |
-1.37 |
3.24e-1 |
125/155 (80.65%) |
FZD8;HSD3B1;AGTR1;...
|
| Cellular senescence |
-1.38 |
3.12e-1 |
139/156 (89.1%) |
CAPN2;SIRT1;ITPR2;...
|
| Fat digestion and absorption |
-1.38 |
3.18e-1 |
35/43 (81.4%) |
SCARB1;APOA4;DGAT1;...
|
| Hepatocellular carcinoma |
-1.39 |
3.19e-1 |
135/168 (80.36%) |
E2F2;FRAT2;LRP5;...
|
| Pathways in cancer |
-1.41 |
2.71e-1 |
474/531 (89.27%) |
SKP2;IL23A;E2F2;...
|
| Breast cancer |
-1.43 |
2.43e-1 |
119/147 (80.95%) |
PIK3R1;PIK3R2;MAP2K2;...
|
| Diabetic cardiomyopathy |
-1.43 |
2.53e-1 |
162/203 (79.8%) |
NDUFAB1;VDAC3;NDUFA9;...
|
| Gastric cancer |
-1.46 |
2.16e-1 |
122/149 (81.88%) |
PIK3R1;PIK3R2;MAP2K2;...
|
| NF-kappa B signaling pathway |
-1.46 |
2.26e-1 |
90/104 (86.54%) |
IKBKB;CSNK2A2;TRAF1;...
|
| Wnt signaling pathway |
-1.47 |
2.24e-1 |
124/166 (74.7%) |
MAP3K7;DAAM2;TBL1XR1;...
|
| Taurine and hypotaurine metabolism |
-1.50 |
1.93e-1 |
8/11 (72.73%) |
GAD1;GGT1;ADO
|
| Parkinson disease |
-1.50 |
2.02e-1 |
176/249 (70.68%) |
CALML5;SDHD;NDUFA6;...
|
| PPAR signaling pathway |
-1.50 |
2.10e-1 |
66/74 (89.19%) |
RXRB;SORBS1;ACAA1;...
|
| Transcriptional misregulation in cancer |
-1.51 |
2.24e-1 |
158/192 (82.29%) |
DEFA4;SPINT1;IL6;...
|
| Hematopoietic cell lineage |
-1.53 |
1.89e-1 |
90/99 (90.91%) |
HLA-DMB;MME;ITGA4;...
|
| Basal cell carcinoma |
-1.56 |
1.65e-1 |
41/63 (65.08%) |
BMP2;TCF7;BAX;...
|
| TGF-beta signaling pathway |
-1.57 |
1.70e-1 |
81/94 (86.17%) |
GREM1;BMP2;ID4;...
|
| Primary immunodeficiency |
-1.61 |
1.44e-1 |
33/38 (86.84%) |
CD40LG;IGLL1;CD79A;...
|
| DNA replication |
-1.62 |
1.47e-1 |
34/36 (94.44%) |
MCM6;MCM5;MCM2;...
|
| Proteoglycans in cancer |
-1.64 |
1.47e-1 |
172/205 (83.9%) |
SDC2;FZD2;SMAD2;...
|
| Non-homologous end-joining |
-1.69 |
1.09e-1 |
11/13 (84.62%) |
LIG4;MRE11;DNTT
|
| Small cell lung cancer |
-1.71 |
1.12e-1 |
90/92 (97.83%) |
PIK3R1;LAMB2;PIK3R2;...
|
| p53 signaling pathway |
-1.72 |
1.39e-1 |
63/73 (86.3%) |
TP53;PMAIP1;CCNE1;...
|
| Signaling pathways regulating pluripotency of stem cell... |
-1.81 |
9.42e-2 |
110/143 (76.92%) |
ONECUT1;BMPR1B;BMP4;...
|
| Hippo signaling pathway |
-1.88 |
8.92e-2 |
120/186 (64.52%) |
BMP5;WNT7A;AMH;...
|
